11 completed, 9 active not recruiting, 5 recruiting, 1 terminated. 27 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 27 | Completed 11, Active not recruiting 9, Recruiting 5, Terminated 1, Withdrawn 1 |
| Phase 2 | 1 | Active not recruiting 1 |
Follow 5FU: new trials by email Literature Review of 5FU trials Research Report on 5FU
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial Bevacizumab, Biopsy Procedure, Biospecimen Collection - Metastatic Appendix Carcinoma, Metastatic Colorectal Carcinoma | Phase 3 | Recruiting | City of Hope Medical Center | 129 | 2027-01-04 | 2026-11-05 |
| Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations Biospecimen Collection, Computed Tomography, Fluorouracil - Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma | Phase 3 | Recruiting | SWOG Cancer Research Network | 94 | 2026-05-13 | 2026-05-22 |
| Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study Biospecimen Collection, Cisplatin, Computed Tomography - Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8 | Phase 3 | Recruiting | NRG Oncology | 486 | 2025-10-07 | 2026-10-23 |
| Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer Biopsy Procedure, Biospecimen Collection, Capecitabine - Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8 | Phase 3 | Recruiting | NRG Oncology | 356 | 2025-08-21 | 2026-08-25 |
| Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial Bevacizumab, Capecitabine, Cetuximab - Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver | Phase 3 | Recruiting | ECOG-ACRIN Cancer Research Group | 408 | 2024-04-10 | 2026-09-24 |
| Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck Carboplatin, Cisplatin, Computed Tomography - Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma | Phase 3 | Active not recruiting | ECOG-ACRIN Cancer Research Group | 290 | 2023-06-08 | 2026-09-14 |
| Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension Pembrolizumab, Placebo, Cisplatin - Gastric Cancer, Gastroesophageal Junction Cancer | Phase 3 | Completed | Merck Sharp & Dohme LLC | 120 | 2020-07-29 | 2026-03-06 |
| Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body Capecitabine, Fluorouracil, Leucovorin - Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8 | Phase 3 | Active not recruiting | ECOG-ACRIN Cancer Research Group | 314 | 2020-05-26 | 2026-10-19 |
| Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer Biospecimen Collection, Capecitabine, Carboplatin - Clinical Stage I Esophageal Adenocarcinoma AJCC v8, Clinical Stage I Esophageal Squamous Cell Carcinoma AJCC v8 | Phase 3 | Active not recruiting | NRG Oncology | 300 | 2019-06-26 | 2026-08-24 |
| Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer Atezolizumab, Biopsy of Bladder, Cisplatin - Bladder Urothelial Carcinoma, Muscle Invasive Bladder Carcinoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 475 | 2019-06-03 | 2026-11-12 |
| Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859) Pembrolizumab, Cisplatin, 5-fluorouracil - Stomach Neoplasms | Phase 3 | Completed | Merck Sharp & Dohme LLC | 1579 | 2018-11-08 | 2026-02-27 |
| Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)-China Extension Pembrolizumab, Cisplatin, 5-fluorouracil - Stomach Neoplasms | Phase 3 | Withdrawn | Merck Sharp & Dohme LLC | 2018-11-08 | 2021-12-16 | |
| Adjuvant Systemic Chemotherapy With or Without HAI-FUDR in Patients With Resected CRLM FUDR, Oxaliplatin, Leucovorin - Colorectal Cancer, Liver Metastases | Phase 3 | Terminated | Sun Yat-sen University | 92 | 2018-05-28 | 2024-01-22 |
| Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery Biospecimen Collection, Carboplatin, Cisplatin - Childhood Hepatocellular Carcinoma, Childhood Malignant Liver Neoplasm | Phase 3 | Active not recruiting | Children's Oncology Group | 537 | 2018-05-24 | 2026-09-14 |
| Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study Atezolizumab, Bevacizumab, Biospecimen Collection - Metastatic Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v7 | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 120 | 2018-01-19 | 2026-11-12 |
| Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair Atezolizumab, Biospecimen Collection, Computed Tomography - Colon Adenocarcinoma, DNA Repair Disorder | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 712 | 2017-10-16 | 2026-11-13 |
| Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585) Pembrolizumab, Placebo, Cisplatin - Gastric Cancer, Gastroesophageal Junction Cancer | Phase 3 | Completed | Merck Sharp & Dohme LLC | 1007 | 2017-10-09 | 2026-03-09 |
| Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA Bone Scan, Cisplatin, Clinical Observation - EBV Infection, Stage II Nasopharyngeal Carcinoma AJCC v7 | Phase 2 / Phase 3 | Active not recruiting | NRG Oncology | 924 | 2014-07-01 | 2026-11-12 |
| Phase 3 Study of FOLFIRINOX (mFFX) +/- SBRT in Locally Advanced Pancreatic Cancer Oxaliplatin, Irinotecan, Leucovorin - Pancreatic Cancer | Phase 3 | Completed | Stanford University | 27 | 2013-08-14 | 2022-10-28 |
| Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery 3-Dimensional Conformal Radiation Therapy, Biospecimen Collection, Capecitabine - Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma | Phase 3 | Completed | National Cancer Institute (NCI) | 546 | 2010-04-05 | 2026-02-23 |
Showing 20 of 27. Sign in to see all of them.
Colorectal Neoplasms (6) · Parkinson Disease 4, Autosomal Dominant Lewy Body (4) · Stomach Neoplasms (4) · Colonic Neoplasms (3) · Pancreatic Neoplasms (3) · Squamous Cell Carcinoma of Head and Neck (2) · Urinary Bladder Neoplasms (2) · Adenocarcinoma Of Esophagus (1) · Appendiceal Neoplasms (1) · Carcinoma (1) · Colorectal Neoplasms, Hereditary Nonpolyposis (1) · DNA Repair-Deficiency Disorders (1) · Epstein-Barr Virus Infections (1) · Fibrolamellar hepatocellular carcinoma (1) · Hepatoblastoma (1)
National Cancer Institute (NCI) (8) · Merck Sharp & Dohme LLC (4) · NRG Oncology (4) · ECOG-ACRIN Cancer Research Group (3) · Children's Oncology Group (2) · City of Hope Medical Center (1) · Gruppo Oncologico del Nord-Ovest (1) · SWOG Cancer Research Network (1) · Stanford University (1) · Sun Yat-sen University (1) · US Oncology Research (1)
United States (23) · Canada (11) · China (6) · Puerto Rico (6) · Australia (5) · Brazil (3) · Germany (3) · Israel (3) · Italy (3) · Japan (3) · South Africa (3) · Taiwan (3) · Belgium (2) · Chile (2) · France (2)
Al B Benson (1) · Alfredo Falcone, MD (1) · Allen Cohn, MD (1) · Carlos Rodriguez-Galindo (1) · Carmen J Allegra (1) · Daniel T Chang (1) · David J Sher (1) · Frank A Sinicrope (1) · Gregory M Tiao (1) · Howard M Katzenstein (1) · Leonard Saltz, M.D. (1) · Michael Lidsky (1)
PMID 21997132, PMID 23233715, PMID 26861604, PMID 28006055, PMID 30777447, PMID 30975630, PMID 31268130, PMID 31553639, PMID 31618129, PMID 31657981, PMID 31811950, PMID 33356421, PMID 33370024, PMID 33975465, PMID 34874751, PMID 35602670, PMID 35623069, PMID 37073741, PMID 37222189, PMID 37598723, PMID 37875143, PMID 38131628, PMID 38134948, PMID 38315963, PMID 39644535, PMID 39938471, PMID 40025394, PMID 40750941, PMID 40829093, PMID 40953502, PMID 41005671, PMID 41880612, PMID 41964430, PMID 42456089, PMID 42525921
U10CA180868 (6), U10CA180820 (5), U10CA180886 (3), 2018 (2), 2023 (2), U10CA021115 (2), U10CA021661 (2), U10CA098543 (2), U10CA180888 (2), P30CA033572 (1), U10CA012027 (1), U10CA180821 (1), U10CA180822 (1), U10CA180830 (1)